Religious Orders Study

Religious Orders Study
Name	Religious Orders Study
Established	1993
Location	Chicago, Illinois
Affiliated institution	Rush University Medical Center
Field	Alzheimer's disease research
Directors	David A. Bennett
Participants	n.a.

Religious Orders Study

The Religious Orders Study is a longitudinal clinical-pathologic cohort investigating Alzheimer's disease, cognitive decline, and aging-related neuropathology. Launched by investigators at Rush University Medical Center and associated with researchers such as David A. Bennett (neurologist), the project pairs annual clinical evaluations with brain donation to link antemortem cognitive trajectories to postmortem findings. The cohort has informed work across domains including neuroimaging, epidemiology, neuropathology, and biomarkers.

Overview

The study began as a collaboration among clinicians and scientists at Rush University Medical Center, the National Institute on Aging, and religious communities in the United States. It enrolls clergy and religious order members who consent to annual neurologic and neuropsychological testing and brain donation at death, generating a unique dataset used alongside cohorts such as the Memory and Aging Project and the Alzheimer's Disease Neuroimaging Initiative. Outcomes include clinical diagnoses of Alzheimer's disease, characterization of mild cognitive impairment, and neuropathologic measures like neurofibrillary tangles and amyloid plaques.

Methods and Study Design

The protocol integrates standardized annual clinical assessments, structured neuropsychological batteries, and structured neuropathologic evaluation using consensus criteria such as the National Institute on Aging–Alzheimer's Association guidelines. Neuropsychological testing includes instruments referenced in studies from the National Institutes of Health, and neuropathology follows methods akin to those used in the CERAD protocol and Braak staging. Data linkage allows correlation of longitudinal cognitive metrics with postmortem measures of Lewy body disease, vascular lesions, and mixed pathologies. The design supports multi-omic analyses including genome-wide association studies, transcriptomics, and proteomics.

Participant Cohort and Recruitment

Participants are predominantly members of Roman Catholic and other religious communities from across the United States, recruited through associations with convents, monasteries, and clerical organizations. Enrollment emphasized willingness for brain donation, enabling high autopsy rates; this approach contrasts with community-based cohorts such as the Framingham Heart Study and complements population studies like the Nun Study. Demographic data capture age, sex, education, and lifestyle factors; genetic data include APOE genotyping and wider arrays used in consortia such as the Alzheimer's Disease Genetics Consortium.

Key Findings and Publications

Analyses from the cohort have produced influential publications linking clinicopathologic measures to cognitive outcomes. Findings include demonstration of the prevalence of mixed pathologies combining Alzheimer pathology with cerebrovascular disease and Lewy body pathology, quantification of the impact of resilience factors on clinical expression, and identification of molecular signatures associated with cognitive resilience. High-impact articles have appeared in journals frequently cited alongside work from the International Genomics of Alzheimer's Project and the Religious Orders Study and Memory and Aging Project (ROSMAP) collaborations. Investigations have reported associations between lifestyle variables and cognitive trajectories, interactions of APOE alleles with pathology, and omics-derived targets later explored in translational platforms such as proteomics and single-cell RNA sequencing studies.

Impact on Alzheimer’s Disease Research

The cohort has shaped understanding of heterogeneity in Alzheimer's disease presentation, influencing diagnostic criteria and biomarker development used by groups like the Alzheimer's Association and the National Institute on Aging. Its high autopsy rate and richly phenotyped participants contributed to discovery of novel molecular pathways implicated in neurodegeneration and cognitive resilience, informing follow-up work in translational efforts at institutions such as Massachusetts General Hospital, Johns Hopkins University, and Columbia University Irving Medical Center. Cross-cohort meta-analyses leveraging its data have supported initiatives by consortia including the AMP-AD program.

Ethical Considerations and Data Sharing

Ethical oversight adheres to standards set by institutional review boards such as those at Rush University Medical Center and guidance from the National Institutes of Health. Informed consent procedures cover longitudinal assessment and brain donation, addressing autonomy and postmortem tissue use. Data sharing practices align with federated and public-access models used in biomedical research, contributing deidentified clinical, neuropathologic, and molecular data to repositories that collaborate with projects like the Accelerating Medicines Partnership–Alzheimer's Disease and public databases used by the Genotype-Tissue Expression Project. Governance balances participant confidentiality with scientific transparency and collaborative research.

Category:Alzheimer's disease studies Category:Neurology research cohorts